The Autoimmune Opportunity is Growing.
So is the Complexity.
Autoimmune drug development is no longer defined by volume alone. Developers are navigating a crowded and increasingly selective market, where emerging mechanisms, cell-based approaches, shifting trial activity, and high-value transactions are reshaping the competitive landscape. This report helps you see where the field is moving next, from the rise of CAR-T and in vivo CAR approaches to sustained investment in B-cell and plasma-cell depletion strategies, growing pivotal trial activity, and a deals landscape where fewer transactions are carrying greater strategic weight. With 668 drugs and 976 trials added in H1 2026, the report turns a rapidly expanding market into clear, decision-ready insight.
Report Contents
The Drug Landscape
Explore the assets, targets, modalities and disease areas driving autoimmune innovation in H1 2026, including rising interest in CAR-T, in vivo CAR and deep immune-reset strategies.
The Trial Landscape
Track where clinical activity is accelerating, which diseases are attracting new trial initiations, and how positive status changes are signalling continued pipeline progression.
The Commercial Landscape
Understand how autoimmune dealmaking is evolving, with H1 2026 recording the lowest deal count in five years but the second-highest period by potential deal value, pointing to a more concentrated, high-value market.
The Future of Autoimmune Development
Look ahead to the trials, assets and readouts that could define the second half of 2026 and beyond, including 688 trials anticipated to conclude in H2 2026.
Regulatory Announcements
Review the regulatory milestones shaping development momentum, from Investigational New Drug (IND) and Clinical Trial Application (CTA) approvals to orphan designations, Biologics License Application (BLA) approvals and early regulatory interactions.
Previous Autoimmune Landscape Reviews
Autoimmune 2025 Landscape Review
An analysis of the Autoimmune landscape in 2025
Autoimmune H1 2025 Landscape Review
An analysis of the Autoimmune landscape in H1 2025
Recent Autoimmune Resources
Learn More About Autoimmune
- The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
- Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
